我觉得外加物料少不见得是好事。主药的含量均匀度问题不大,但是崩解剂混不匀的话,会不会影响溶出(到底会不会影响,得看看当初研发时崩解剂算不算敏感的CMA)。也得提供这台总混机上做过的验证数据,帮助说明外加物料较少时风险是否较低。
严格的讲,按SFDA发布的《已上市化学药品变更研究的技术指导原则(一)》#五、变更药品制剂的生产工艺,提到II类变更是“这种变更包括无菌制剂生产中采用相同设计及操作原理的设备替代另一种设备;非无菌制剂生产中采用设计及操作原理不同的设备替代另一种设备;改变半固体制剂生产中混合设备类型,由高速剪切机变更为低速剪切机,或相反变更。” 字面意思恰好把固体制剂同原理设备变换跳过去了。
个人觉得混合均匀性还是得验证(这一步的物料确不怎么影响含量均匀度,但之前有没有预混,混合均匀性会不会受这一步影响?),做不做溶出也看产品属性,稳定性研究感觉没有必要。
当然,你们省局管不管这个,要比我的意见重要。
可以真针对变更项做验证,即混合均匀度;但按照《已上市化学药品变更研究的技术指导原则(一)》的要求,属于变更操作原理的变更,属于重大变更,虽然我对此有异议。
If ssume a normal bulk density of 0.5 (gm/mL) then the 76 Kg of powder blend will just occupy about 150 L, your original situation that there is about 7.5% of total blender volume. It is well outside the "usual and customary" blender volume fill. Most people regard a good working fill volume for a V-blender to be between 20% and 80% of total blender volume. Using your 150 L batch volume estimate, this would be 37.5% filled, which is well within the usual fill range.
You are effectively making 3 changes, a change in blender subclass, a big change in total blender volume, and a big change in actual blend volume in the blender.According to SUPAC Manufacturing Equipment Addendum Guidance, A V-blender and a Bin Blender are the same class (Diffusion Mixers, or Tumble) but different subclass. You might well be asked for validation of this big change of blender actual fill volume.
According to SUPAC-IR and to the Changes guidance, this change is a CBE-30 change (level 2). You will need to provide blend uniformity data from the blender before and after the change. Uniformity data plus all the other testing and putting the first commercial batch from the "new" process on stability would satisfy the filing requirements for this change. However, process validation is a compliance issue (not filed).
这{{threadTextType}}正{{isAdminText}}
为帮助审核人员更快处理,请填写举报原因:
为帮助审核人员更快处理,请填写举报原因: